Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer

SIMPLE SUMMARY: It remains unclear why chemotherapy is often ineffective in patients with bladder cancer. Meanwhile, we previously reported that male sex hormones (i.e., androgens) could considerably reduce the efficacy of cisplatin, an anti-cancer drug used as the first-line treatment against advan...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Jiang, Guiyang, Teramoto, Yuki, Goto, Takuro, Mizushima, Taichi, Inoue, Satoshi, Ide, Hiroki, Nagata, Yujiro, Kashiwagi, Eiji, Baras, Alexander S., Netto, George J., Yang, Zhiming, Miyamoto, Hiroshi
Format: Artigo
Langue:Inglês
Publié: MDPI 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7956795/
https://ncbi.nlm.nih.gov/pubmed/33652650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13050975
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires